01Overview 02Daily Brief 03Live 04Congress 05Corporate Insiders 06Government Money 07Political Influence 08Institutions 09Washington Network 10Follow the Power 11Disclosure Clock 12AI Investigator 13Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…

Overview Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

01Overview 02Daily Brief 03Live 04Congress 05Corporate Insiders 06Government Money 07Political Influence 08Institutions 09Washington Network 10Follow the Power 11Disclosure Clock 12AI Investigator 13Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Overview Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Data sources

SEC FORM 429m ago

HOUSE PTR29m ago

SEC 13F29m ago

ROBINHOOD CHAIN29m ago

Public company

DLBDolby Laboratories, Inc.

CIK 0001308547

EDGAR filings Open in network

Disclosed transactions0

Buys / sells0 / 0

Max Insider Score—

Connections2with evidence

DLB · disclosed activity on price

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

In industryevidence
Banking, securities & insuranceSEC SIC 6794 · Patent Owners & Lessors · Nov 4, 2026
← Lobbied forevidence
ACG ADVOCACYLDA Q1 2026 first quarter · Copyright/patent, Trade · Aug 26, 2026

Lobbying

$100K reported · de-duplicated

2026 Q3 $0 via firms2026 Q2 $50K via firms2026 Q1 $50K via firms

In-house report—2026 Q3 · posted Aug 26, 2026 · Copyright/patent
ACG ADVOCACY$50K2026 Q2 · posted Aug 26, 2026 · Copyright/patent, Trade
ACG ADVOCACY$50K2026 Q1 · posted Aug 26, 2026 · Copyright/patent, Trade

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.